Cross-Sector entity
earnings is the sole category represented across all 1 tracked stories. BioBeat is most often covered alongside Assure system, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention BioBeat, all published on March 18, 2026.
1 verified story tracked
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. BioBeat is most often covered alongside Assure system, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention BioBeat, all published on March 18, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BioBeat. Shared-story counts are live from our verified record — not editorial picks.
Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion. While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
